Safety study of a new hepatitis B antibody for hepatitis D
Treatments studied
Part of Digestive system, Infections clinical trials.
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed hepatitis D infection (positive anti-HDV antibody and detectable HDV RNA in your blood)
- You do not have hepatitis B surface antibody (HBsAb negative) at screening
- Your liver function is not severely damaged—specifically, your Child-Turcotte-Pugh score is 9 or lower
- You have not had serious liver complications like hepatic encephalopathy or bleeding from enlarged veins in the past 12 months
- You agree to contraception if you can become pregnant or impregnate a partner, and you have no serious allergies to monoclonal antibodies or vaccines
- You have not received any vaccines in the past 2 weeks and have no active infections like flu or COVID-19
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Hepalatide for people with chronic hepatitis D (a liver infection). You must already have hepatitis B and be on a stable antiviral for it. The study checks if Hepalatide can safely lower HDV levels.
This study follows adults who have ongoing hepatitis D infection along with hepatitis B. It aims to better understand this mixed infection and how these patients do over time.
This trial tests an experimental antibody treatment for people with chronic hepatitis B who have been on antiviral medication for at least 6 months. It aims to see if the antibody is safe and can help control the virus.
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Hear when a new Hepatitis D, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.